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ORIGINAL INVESTIGATION
Prevalence and incidence of complications 
at diagnosis of T2DM and during follow-up 
by BMI and ethnicity: a matched case–control 
analysis
Ebenezer S. Owusu Adjah1,2, Srikanth Bellary3, Wasim Hanif4, Kiran Patel5,6, Kamlesh Khunti7 
and Sanjoy K. Paul8* 
Abstract 
Aims: To estimate the risk of developing long-term major cardiovascular and renal complications in relation to levels 
of body mass index (BMI) in a population of White European (WE), African-Caribbean (AC), and South Asian (SA) 
patients with type 2 diabetes mellitus (T2DM).
Materials and methods: Patients with new diagnosis of T2DM, aged ≥ 18 years from January 2000 (n = 69,436) and 
their age-sex-ethnicity matched non-diabetic controls (n = 272,190) were identified from UK primary care database. 
Incidence rates ratios (IRRs) for non-fatal major cardiovascular events (MACE) and chronic kidney disease (CKD) in 
patients with T2DM compared to controls were estimated using multivariate Mantel-Cox model.
Results: Among normal weight patients with T2DM, WEs had significantly higher prevalence of cardiovascular multi-
morbidity (95% CI 9.5, 11.3), compared to SAs (95% CI 4.8, 9.5). AC and SA overweight and obese patients had similar 
prevalence, while obese WEs had significantly higher prevalence. During a median 7 years of follow-up, risk of MACE 
was significantly higher for overweight (95% CI of IRR 1.50, 2.46) and obese (95% CI of IRR 1.49, 2.43) SAs compared to 
their WE counterparts. However, similar risk levels were observed for normal weight WEs and SAs, respectively. Risk of 
CKD was higher and uniform for BMI ≥ 25 kg/m2 amongst WEs and ACs, whereas only overweight patients had signifi-
cantly higher risk of CKD amongst SA [IRR 2.08 (95% CI 1.49, 2.93)].
Conclusion: Risk of MACE/CKD varies over levels of BMI within each ethnic group, with overweight SAs having a 
disproportionate risk of CKD.
Keywords: Type 2 diabetes, Body mass index, Complications, Ethnicity, Prevalence, Incidence
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Introduction
Ethnicity remains one of the key risk factors for type 2 
diabetes mellitus (T2DM) and the predisposition of cer-
tain ethnic groups to develop T2DM is now well known 
[1]. Not only does diabetes occur early in some eth-
nic groups [2, 3], but there is also a greater predisposi-
tion to develop diabetes-related complications [4]. This 
disproportionate predisposition of certain ethnic groups 
to T2DM and its complications is commonly attributed 
to the complex interaction of genetic and environmental 
factors [5, 6]. Several studies have compared the preva-
lence and severity of diabetes complications between 
South Asians and White Europeans [7–12]. Although 
some studies have generally reported higher prevalence 
of some complications (particularly nephropathy and 
retinopathy) [11, 13], other studies have shown these dif-
ferences are not as significant as thought [10, 14].
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The UK Prospective Diabetes Study Group (UKPDS) 
evaluated the incidence of myocardial infarction (MI) 
by ethnicity, and found no additional risk of MI among 
South Asian (SA) and African-Caribbean (AC) partici-
pants, respectively compared to White European (WE) 
participants [10]. While this study accounted for some 
cardiovascular risk factors in their risk assessment 
model, body mass index (BMI) which is an important 
cardiovascular risk factor in patients with T2DM was not 
included. Furthermore, while other studies have evalu-
ated the ethnicity related differences in the incidence of 
cardiovascular events in patients with T2DM [9, 15–17], 
no separate assessment of the potential differences in the 
risk paradigm by adiposity levels were evaluated for each 
ethnic group.
Given that BMI and ethnicity play important roles in 
cardiovascular risk profiles of patients with T2DM, we 
are not aware of any study that has evaluated ethnicity 
specific long-term cardiovascular and non-cardiovas-
cular complications in T2DM by BMI categories at the 
population level. Such evaluations are of immense public 
health importance given the increased burden of compli-
cations associated with T2DM [18–20], and will address 
the knowledge gap in terms of the interplay between 
ethnicity, BMI, cardiovascular, and non-cardiovascular 
complications in patients with T2DM [21]. Therefore, the 
aims of this primary care based retrospective longitudi-
nal case–control study were to evaluate (1) comorbidities 
and cardiovascular risk factors at diagnosis of T2DM in 
different ethnic groups, and (2) the likelihood of develop-
ing long term complications by BMI categories in differ-
ent ethnic groups compared to non-diabetic controls.
Methods
Data source
Data from the primary care database of UK [The Health 
Improvement Network (THIN)] was used. Patients 
are registered with one general practitioner (GP) even 
though secondary care treatment can be provided else-
where, and under terms specified by the UK’s National 
Health Service (NHS), GPs contribute data to THIN. 
Thus, daily electronic medical records (EMRs) of patients 
in participating practices are regularly submitted to 
THIN using the INPS ViSion software [22]. The database 
is linked to other sources of hospital and national statis-
tics data and is demographically representative of the UK. 
Currently, data from over 600 general practices involved 
with THIN from 1990 to 2014 is available. The source 
population includes over 13 million patients, 85% of 
whom have records that are considered valid and accept-
able for research. The accuracy and completeness of this 
database have been previously described elsewhere [23, 
24]. This database provides comprehensive patient-level 
longitudinal information on demographic, anthropomet-
ric, clinical and laboratory measures, clinical diagnosis of 
diseases and events, along with complete information on 
prescriptions for medications with dates and doses. Clin-
ically diagnosed diseases are recorded using Read codes 
[25], and with each diagnosis, an event date is entered. 
Similarly, prescriptions are recorded with both British 
National Formulary (BNF) codes and anatomical thera-
peutic chemical (ATC) codes along with their prescrip-
tion dates.
Study population
The primary design and results have already been pub-
lished [2]. Briefly, from THIN database 69,436 patients 
with newly diagnosed T2DM from January 2000 were 
identified using a robust machine-learning algorithm, 
which uses the disease Read codes [25], antidiabetic 
medications, and lifestyle modification interventions as 
feeds. Patients were included if they had (1) complete 
information on age at diagnosis (≥ 18  years) and sex, 
and (2) self-identified ethnicity as WE, AC or SA. South 
Asians (SAs) were defined as patients with Indian, Paki-
stani, Sinhalese, and Bangladeshi origin, while ACs were 
defined as patients with Black-African and/or Caribbean 
origin. White Europeans (WEs) were patients with self-
reported ethnicity as White, European, European, and/
or New Zealand European. Those with Read codes for 
type 1 diabetes mellitus (T1DM) and gestational diabe-
tes were excluded. Non-diabetic patients were patients 
in the THIN database with no diagnosis of any type 
of diabetes and had never received a prescription of an 
anti-diabetes therapy. Up to four non-diabetic control 
patients (n = 272,190) were matched to each identified 
T2DM patient based on age, sex and ethnicity using an 
exact matching algorithm. The index date for controls 
was defined as the date of the diabetes diagnosis for their 
matched cases.
Study variables and outcome measurements
Clinical and demographic variables including smok-
ing status, deprivation score (measure of socioeconomic 
status based on residential address), weight, BMI, gly-
cated haemoglobin (HbA1c), systolic blood pressure 
(SBP), diastolic blood pressure (DBP), low density lipo-
protein cholesterol  (LDL), high density lipoprotein cho-
lesterol (HDL), and triglycerides were extracted for each 
patient where appropriate. All available measures on or 
within 3 months prior to the index date were considered 
as baseline measures. For all clinical parameters, longi-
tudinal data 12  months prior to index date and 2  years 
post index date were extracted on a 6-monthly window. 
Categories for BMI were defined following WHO estab-
lished criteria as follows: normal weight (18.5–24.9  kg/
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m2), overweight (25–29.9  kg/m2), and obese (≥ 30  kg/
m2). For South Asians, BMI in the ranges 18.5–22.9, 
23–27.4, ≥ 27.5 kg/m2 were used to define normal weight, 
overweight and obese patients, respectively [26]. Pre-
scription information on anti-diabetes therapies, antihy-
pertensive agents, cardio-protective medications (CPM), 
weight-lowering drugs and anti-depressants were also 
obtained, where appropriate.
Patients with a recorded diagnosis of stroke, heart fail-
ure (HF), angina, MI, coronary artery disease (including 
bypass surgery and angioplasty), cancer, or renal diseases 
[including chronic kidney disease (CKD)] before diag-
nosis were considered to have relevant comorbidities at 
diagnosis. Subsequently, cardiovascular multi-morbidity 
was defined as ≥ 2 episodes of a major cardiovascular 
conditions at diagnosis. A composite variable for major 
cardiovascular events (MACE) was defined as the occur-
rence of non-fatal MI, HF or stroke during follow-up. 
Time to a specific disease event was calculated as the 
time from diagnosis date to the first occurrence of the 
disease event and patients were censored on the end date 
(September 2014) or on drop out date.
Statistical analysis
Baseline characteristics of patients with incident T2DM 
and their matched non-diabetic controls were summa-
rized using number (%), means (95% CI) or median (first 
quartile, third quartile) as appropriate. Age-sex stand-
ardized proportions of existing comorbidities at diag-
nosis were calculated with indirect standardisation to 
the internal data structure. Age groups (18–40, 41–50, 
51–60, 61–70, and 71+ years) and sex (male vs. female) 
were used to achieve stratum-specific proportions for 
indirect standardisation.
Major cardiovascular event (MACE) and CKD 
(stage ≥ 3) incident rates (rates per 1000 person-years) 
were estimated by BMI categories for T2DM cases and 
controls separately for each ethnic group. To estimate 
MACE and CKD (stage ≥ 3) incidence rate ratio (IRR) for 
T2DM cases compared to controls, a multivariate Man-
tel-Cox model was fitted: adjusting for age, sex, baseline 
SBP, smoking status (current, ex, and never smokers), 
and deprivation score by stratification. Robust estimates 
of IRRs (95% CI) were obtained, and Bayesian informa-
tion criteria (BIC) was used to compare the model fits.
Results
Demographic and clinical characteristics
The demographic and clinical profiles of T2DM patients 
(n = 69,436) and matched non-diabetic controls 
(n = 272,190) are presented in Table 1. Overall, the mean 
age at diagnosis was 57 years, 57% were male, and median 
follow-up time was similar across T2DM cases and 
their non-diabetic controls (7  years). Within subgroups 
defined by ethnicity, T2DM patients and their non-dia-
betic controls were well matched on age and sex distribu-
tions. The distribution of current or ex-smokers in T2DM 
patients and controls were 55 and 50%, respectively, and 
the proportions of patients with SBP ≥ 140 mmHg were 
39 and 18%, respectively.
Compared to WEs and ACs, SAs developed diabetes 
significantly earlier by (~ 10 and 2  years) and at lower 
BMI (3 and 2 kg/m2, Table 1). More SAs (66%) developed 
T2DM within the age of 50  years, while 27 and 59% of 
WEs and ACs developed the disease within the same 
age limit, respectively. Significantly higher proportions 
of WE cases and controls had SBP above 140 mmHg (41 
and 21%), compared to ACs (30 and 12%) and SAs (23 
and 9%), respectively.
Prevalence of comorbidities at diagnosis
T2DM cases had a significantly higher proportion of 
existing comorbidities at diagnosis compared to controls 
(27% vs. 18%, Table  1). The prevalence (95% CI) of car-
diovascular complications at diagnosis by BMI categories 
among patients with T2DM, separately for each ethnic 
group are presented in Table  2. Among normal weight 
patients with T2DM, WEs had significantly higher prev-
alence of cardiovascular multi-morbidity (prevalence 
10.4%; 95% CI 9.5, 11.3), compared to SAs (prevalence 
6.8%; 95% CI 4.8, 9.5), but had similar prevalence com-
pared to ACs (prevalence; 95% CI 4.0, 10.4). African-Car-
ibbean and SA overweight and obese patients had similar 
prevalence of cardiovascular multi-morbidity across all 
adiposity levels, while obese WEs had significantly higher 
risk compared to their normal weight population and 
also compared to other ethnic groups (Table 2).
The prevalence of cardiovascular and non-cardiovas-
cular diseases at diagnosis between T2DM cases and 
their non-diabetic controls, separately for each ethnic 
group are presented in Fig. 1 and Additional file 1: Fig-
ure S1 respectively. White Europeans with or without 
diabetes had significantly higher prevalence of cancer, 
compared to SA cases and controls (Additional file  1: 
Figure S1A). The prevalence of depression among WE 
cases and controls were significantly higher (95% CI of 
proportion—cases 21.8–22.5%; controls 17.3–17.5%) 
compared to other ethnic groups, while SA and AC 
cases and controls had similar prevalence (range of 95% 
CI of prevalence 6.6–9.7%). The prevalence of CKD at 
diagnosis was similar across all ethnic groups and did 
not differ significantly between T2DM cases and their 
non-diabetic controls (Additional file 1: Figure S1).
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Incidence of major cardiovascular diseases 
during follow-up
In individuals without any history of comorbidities at 
index date, the rates per 1000 person-years and incidence 
rate ratios for non-fatal major cardiovascular events and 
chronic kidney disease during follow-up in patients with 
T2DM, compared to non-diabetic controls, are presented 
in Additional file  1: Tables S1 and S2, and Fig.  2 sepa-
rately for ethnic groups and BMI categories at index date.
Overall, the risk of developing MACE in patients with 
T2DM, compared to non-diabetic controls, were similar 
for WEs (95% CI of IRR 1.29, 1.38) and ACs (95% CI of 
IRR 1.34, 2.25), but significantly higher for SAs (95% CI 
of IRR 1.56, 2.22) compared to WEs (Additional file  1: 
Table S1).
The risk of developing MACE was significantly higher 
for overweight (95% CI of IRR 1.50, 2.46) and obese (95% 
CI of IRR 1.49, 2.43) SAs compared to their WE counter-
parts (95% CI of IRR 1.29, 1.42 in overweight; 1.29, 1.43 
in obese). However, similar risk levels were observed for 
WEs and SAs who were normal weight (Fig.  2a, Addi-
tional file 1: Table S1).
White European patients with T2DM had similar 
rates of MACE (range of 95% CI of rate/1000 person-
years 10.55, 14.66, Additional file  1: Table S1) across all 
BMI level, and these rate estimates were almost two-fold 
Table 2 Age-sex adjusted prevalence (95% CI) 
of  cardiovascular complications at  diagnosis by  BMI 
categories among patients with T2DM, separately for each 
ethnic group
Prevalence (95% CI)
MACE MI HF STROKE
Normal weight
 White Euro-
pean
10.4 (9.5, 11.3) 4.6 (4.0, 5.2) 4.6 (4.1, 5.2) 5.0 (4.4, 5.6)
 African-Car-
ibbean
6.5 (4.0, 10.4) 2.0 (0.9, 4.9) 2.1 (0.9, 4.7) 4.2 (2.3, 7.7)
 South Asian 6.8 (4.8, 9.5) 4.0 (2.6, 6.2) 4.0 (2.6, 6.2) 3.1 (1.8, 5.1)
Overweight
 White Euro-
pean
11.7 (11.3, 12.2) 6.1 (5.7, 6.5) 6.1 (5.7, 6.5) 5.2 (4.9, 5.6)
 African-Car-
ibbean
7.2 (5.1, 9.9) 2.1 (1.0, 4.1) 2.1 (1.0, 4.1) 4.9 (3.4, 7.2)
 South Asian 9.0 (7.4, 10.9) 5.3 (4.1, 6.9) 5.3 (4.1, 6.9) 3.7 (2.7, 5.1)
Obese
 White Euro-
pean
12.6 (12.3, 12.9) 6.5 (6.3, 6.7) 6.5 (6.3, 6.7) 5.4 (5.2, 5.6)
 African-Car-
ibbean
5.5 (4.1, 7.4) 1.1 (0.5, 2.5) 1.1 (0.5, 2.5) 4.4 (3.2, 6.2)
 South Asian 8.5 (6.2, 11.7) 4.7 (2.9, 7.4) 4.7 (2.9, 7.4) 2.5 (1.5, 4.1)
Fig. 1 Age-sex standardised proportions [% (95 CI)] of macrovascular diseases at diagnosis for patients with T2DM and their matched controls, 
separately for each ethnic group. a The proportion of patients with at least one episode of a macrovascular event at diagnosis; b The proportion 
of patients with two or more episodes of a macrovascular disease events at diagnosis. [HF Heart failure; MACE Three (3) point major cardiovascular 
event defined as the occurrence of myocardial infarction, heart failure or stroke before diagnosis]. WE White European; AC African-Caribbean; SA 
South Asian
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higher compared to that across all adiposity levels in ACs 
(range of 95% CI of rate/1000 person-years 2.96, 8.78) 
and SAs (range of 95% CI of rate/1000 person-years 4.69, 
12.91, Additional file 1: Table S1).
Incidence of chronic kidney disease (stage 3 and above) 
during follow-up
Across all BMI categories, the rates of CKD were con-
sistently higher among WE cases (range of 95% CI of IR 
12.89, 19.73) and controls (range of 95% CI of IR 6.31, 
8.48), compared to AC cases (range of 95% CI of IR 3.04, 
10.89) and controls (range of 95% CI of IR 2.52, 7.20), 
and SA cases (range of 95% CI of IR 2.66, 9.21) and con-
trols (range of 95% CI of IR 1.11, 3.54, Additional file 1: 
Table  S2). While obese WEs with T2DM had signifi-
cantly lower CKD incidence rate compared patients with 
BMI < 30 kg/m2, the observed CKD incidence rates were 
similar across all BMI groups in WEs without diabetes. 
The incidence rates for CKD were similar across all BMI 
categories among AC and SA cases. Obese SAs with dia-
betes had almost half the incidence rate for CKD (IR 3.9) 
compared to ACs (IR 7.3) and about one-fourth com-
pared to WEs (IR 13.4).
The risk of developing CKD in normal weight and obese 
patients with T2DM, compared to non-diabetic controls, 
was significantly higher among WEs only (Fig. 2b). How-
ever, overweight individuals with T2DM had significantly 
higher and similar risk of developing CKD (range of 95% 
CI of IRR 1.5, 3.4), across ethnic groups (Fig.  2b, Addi-
tional file 1: Table S2).
Discussion
This longitudinal case–control study of patients with 
newly diagnosed T2DM and their matched non-diabetic 
controls evaluated the prevalence of comorbidities at 
diagnosis of T2DM and the risk of developing long-term 
major cardiovascular and renal complications by BMI 
categories in different ethnic groups. There are several 
important findings from our study. Firstly, the relation-
ship between obesity and risk of MACE/CKD does not 
appear to be linear. Secondly, at all levels of BMI, diabe-
tes is associated with significantly greater risk of MACE. 
Thirdly, there are important distinctions between the 
ethnic groups, with South Asians showing greater sus-
ceptibility to MACE and CKD even at lower BMI levels.
Obesity is a major risk factor for T2DM and is an inde-
pendent risk factor for cardiovascular disease (CVD) as 
well as CKD [27, 28]. Few studies, however, have explored 
the relationship between levels of adiposity and CVD 
in patients with T2DM and any underlying differences 
between ethnic groups given their differential suscep-
tibility to T2DM. The large size of our cohort matched 
with a non-diabetic control population has allowed us to 
not only compare the effects of obesity on people with 
and without diabetes within each ethnic group but also to 
examine the differences between ethnic groups.
The independent effect of BMI on CVD risk has been 
confirmed in several population studies. Moreover, the 
linearity of this relationship has been shown in both Cau-
casian and Asian populations. In a study involving Asian 
population, the risk of CVD increased significantly with 
each 2 kg/m2 increase in BMI [29]. In patients with dia-
betes, however, this relationship is less clear and exist-
ing data suggest that the relationship may not be linear 
[30]. In our study, we did not find a linear relationship 
between BMI and CVD or between BMI and CKD. On 
the contrary, our data show that patients with diabetes 
have same or even greater degree (in the case of SAs) of 
risk even when they are of normal weight. The absence 
of this linear relationship between BMI and CVD may be 
due to the fact that the mechanisms by which BMI and 
diabetes influence CVD risk are different. Alternatively, 
the higher burden of other known risk factors for CVD 
(i.e., hypertension, dyslipidaemia and insulin resistance) 
seen in patients with diabetes could have a greater impact 
on the overall CVD risk thus mitigating the effects of 
obesity. In this context it is worth noting that interven-
tions in patients with diabetes targeting weight loss have 
been less successful in lowering cardiovascular (CV) risk 
[31].
Across all ethnic groups, diabetes was associated with 
greater risk of MACE. This relationship did not change 
with levels of adiposity, except in ACs, suggesting that 
in some ethnic groups diabetes confers excess risk of 
MACE. These findings are not surprising given that 
patients with diabetes have a significantly greater burden 
of CV risk factors and are likely to be exposed to these 
risk factors for a much longer time. Similar trends were 
Fig. 2 Adjusted incidence rate ratios [IRR (95% CI)] for MACE, and 
CKD in T2DM cases vs. matched non-diabetic controls without 
established comorbidities at index date. Data are presented 
separately by ethnicity for each BMI category at index date. WE White 
European; AC African-Caribbean; SA South Asian
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observed in relation to CKD, except in SAs, where the 
overall risk of CKD amongst diabetic and non-diabetic 
controls was similar in the overweight group, diabetes 
was associated with increased risk. Our data show that in 
addition to the elevated HbA1c, a greater proportion of 
patients with diabetes had poorly controlled blood pres-
sure, elevated triglycerides and more likely to be obese or 
overweight than their non-diabetic counterparts. Despite 
the adverse risk profile, the use of cardio and reno-pro-
tective agents such as statins and ACE inhibitors was low 
suggesting there may have been opportunities for better 
control of risk factors. It must however, be noted that 
these figures date back to the year 2000 and that manage-
ment of these known risk factors has improved consider-
ably since then [32].
Although there are many common features, our data 
has highlighted important differences between ethnic 
groups. As expected, SAs were significantly younger than 
WEs and ACs whereas, WEs were more likely to have a 
diagnosis of cancer or depression and had higher systolic 
blood pressure levels. The overall IR for MACE and CKD 
was significantly greater amongst WEs compared to ACs 
or SAs and this risk was evenly distributed amongst all 
levels of adiposity in WEs. On the other hand, the risk 
of MACE and CKD was greater for SAs who were either 
normal and/or overweight when compared to WEs. We 
have previously shown that SAs develop diabetes much 
earlier and at significantly lower BMI than other ethnic 
groups [2]. It is possible that exposure to diabetes at a 
much younger age may result in adverse vascular profile 
which in turn influences the risk of MACE and CKD. It is 
well known that SAs have excess visceral adiposity which 
may contribute to the overall metabolic risk in this ethnic 
group even at lower levels of BMI. It is also possible that 
BMI may not be an ideal measure of adiposity in SA and 
other measures such as waist/hip ratio could instead be 
more appropriate when assessing adiposity in this ethnic 
group [33]. While there is a need for better understand-
ing of the effects of adiposity on MACE/CKD in different 
ethnic groups, the clear message from this study is to rec-
ognise that SAs have a disproportionate risk of cardiovas-
cular disease even at normal BMI.
Although the large multi-ethnic cohort and the avail-
ability of longitudinal data for a population sharing the 
same health care system have been the strengths of this 
study, it has some limitations. First, there were small 
number of events in BMI subgroups among African-
Caribbean and South Asians. Second, we have in this 
study used BMI as a measure of obesity and it can be 
argued that BMI is not an ideal measure of obesity 
especially in certain ethnic groups such as SA. We are 
aware that this may have limited our ability to explore 
the relationship between adiposity and the risks of 
MACE/CKD. On the other hand, BMI is a commonly 
used measure of obesity and is well recorded than other 
measures such as waist/hip or waist/height ratios. Fur-
ther, we have used ethnic-specific cut-offs for BMI 
[26] to provide as reliable an estimate of adiposity as 
possible.
Our understanding of the differences between ethnic 
groups towards susceptibility to diabetes has improved 
considerably in recent times. The findings of this study 
add to this knowledge and provide a greater under-
standing of the relationship between levels of adiposity 
and diabetes complications in different ethnic groups. 
The results of this study should enable clinicians to bet-
ter diagnose and manage diabetes amongst people of 
different ethnicities.
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